Exelixis Inc (EXEL) Company Profile & Statistics

Exelixis Inc
EXEL
(Nasdaq - US)
Closed
22.50
+0.01 (+0.04%)
in:usd•As of: Apr 19, 2024 15:59 UTC -4
Open
22.54
High
22.71
Low
22.23

About Exelixis Inc

CEO

Michael M. Morrissey

Headquarters

1851 harbor bay parkway

alameda, ca 94502, united states

Auditor

Ernst & Young LLP

Employees

1,310

Share Holders

333

Website

www.exelixis.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Exelixis Inc Statistics

Valuation Measures

Market Capitalization ²	6.82B
Enterprise Value	6.56B
Enterprise Value/EBITDA (ttm)	33.36
Price to Earnings Ratio (ttm)	35.73
Price to Book (mrq)	3.06
Price to Sales (ttm)	3.79
Price to Cash (ytd)	29.70

Profitability

Gross Margin (ttm)	96.05%
Operating Margin (ttm)	11.35%
Profit Margin (ttm)	11.28%
Return on Equity (ttm)	8.57%
Return on Invested Capital (ttm)	8.60%
Return on Assets (ttm)	6.81%

Income Statement

Revenue (ttm)	1.83B
Revenue Per Share (ttm)	6.04
Gross Profit (ttm)	1.76B
EBITDA (ttm)³	196.60M
Net Income Avi to Common (ttm)	207.76M
Diluted EPS (ttm)	0.64

Share Statistics

Beta (5Y Monthly)	0.54
52-Week Change	18.98%
S&P500 52-Week Change	20.28%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	303.19M
Dividend Yield	0.00%
Float ⁴	294.40M
% Held by Insiders	2.90%
% Held by Institutions	85.27%

Balance Sheet

Total Cash (mrq)	995.30M
Total Cash Per Share (mrq)	3.28
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	3.34%
Quick Ratio (mrq)	3.30%
Book Value Per Share (mrq)	7.48

Cash Flow

Operating Cash Flow Per Share (ytd)	1.04
Free Cash Flow (ytd)	170.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Exelixis Inc

Trade With A Regulated Broker